Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Kasper, Bernd; Sleijfer, Stefan; Litière, Saskia; Marréaud, Sandrine; Verweij, Jaap; Hodge, Rachel; Bauer, Sebastian; Kerst, J. Martijn; Graaf, Winette T.A. van der

doi:10.1093/annonc/mdt586

Cited by 98 publications

(88 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the integration of EORTC 62043 and EORTC 62072, good performance status, a low/intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome, and the presence of bone metastases and a low baseline hemoglobin were significant negative factors for pazopanib treatment (22). In deciding the indications for pazopanib, these clinical factors in addition to histological subtypes could be considered; these would correspond to the philosophies of patient-tailored management (6).…”

Section: Discussionmentioning

confidence: 99%

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study

Nakano

Motoi

Inagaki

et al. 2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: In Japan, pazopanib has been made available to soft tissue sarcoma patients, also to patients histologically diagnosed as ineligible for the international Phase 3 study (PALETTE). However, clinical evidence for the use of pazopanib in PALETTE-ineligible patients is currently insufficient. Methods: We retrospectively reviewed medical records of soft tissue sarcoma patients treated with pazopanib at our institute. By pathological review, the patients' eligibility for the PALETTE study was evaluated and the differences in their responses to pazopanib and incidences of adverse events were investigated. Results: From November 2012 to August 2014, a total of 47 patients received pazopanib, 38 (81%) of whom were histologically eligible for the PALETTE study, and 9 of whom (19%) were not. The median follow-up time was 7.5 months (range 1.4-20.3 months). An objective response was observed in both groups, but the patients' survival tended to be longer in the PALETTE-eligible patients; median progression-free survival was 4.5 months vs. 2.9 months (P = 0.15) and overall survival was 10.7 months vs. 7.8 months (P = 0.55), though these differences were not statistically significant. There were no significant differences in the incidence of adverse events by PALETTE eligibility, but dose skipping or dose reduction was more likely to be observed in PALETTE-ineligible patients. Conclusion: Pazopanib is tolerable to soft tissue sarcoma patients ineligible for the PALETTE study and some of them respond to pazopanib, but the prognoses of patients ineligible for the PALETTE study might be worse than those of PALETTE-eligible patients. The indication of pazopanib for soft tissue sarcoma patients with PALETTE-ineligible histologies should be decided carefully.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study

Nakano

Motoi

Inagaki

et al. 2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Combined analysis of the EORTC trial 62,027 and Southwest Oncology Group trial S0345 found a clinical benefit rate greater than 70%, a median time to progression of 1.7 years, and a 1-year overall survival of 87.5%. 164 Kasper and colleagues 165 reported the combined results of a phase II/III (PALETTE) trial involving 118 and 246 patients with STS, respectively, who were treated with pazopanib, a multitargeted tyrosine kinase inhibitor. Combined median survival was 11.7 months, 36% of patients had a PFS greater than 6 months, and 34% had an overall survival longer than 18 months.…”

Section: Other Growth Factors and Their Receptor Tyrosine Kinasesmentioning

confidence: 99%

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

Harwood

Alexander

Mayerson

2015

Orthopedic Clinics of North America

View full text Add to dashboard Cite

“…Továbbá daganatellenes aktivitást mutatott monoterápiában, kiújult vagy metasztatikus angiosarcoma esetén (PFS 3,8 hó-nap [95% CI 2,8-5,5], OS 14,9 hónap [95% CI 9,4-∞], 3 hónapos PFS 64%, 6 hónapos PFS 31%, CR 2,7%, PR 10,8%, SD 56,75%, PD 29,79% [n = 37]), míg SS esetében szerényebb eredményt lehetett elérni: PFS 2,5 hónap (95% CI 1,8-∞), OS 10,3 hónap (95% CI 6,5-∞), 3 hónapos PFS 42%, 6 hónapos PFS 0%, CR 0%, PR 0%, SD 50%, PD 50% (n = 12) [33]. A pazopanib (VEGFR-1, -2, -3, PDGFR és c-Kit inhibitor) -kezeléssel előrehala-dott lágyrész-sarcomában a 2 éves PFS 3,5% [34]. A pazopanib hatását vizsgálják gemcitabin kombinációval, vagy RT+/-KT kombinációval és neoadjuvánsan KT előtt.…”

Section: Célzott Kezelési Lehetőségekunclassified

A sarcoma synoviale kezelési lehetőségei

Deme¹,

Telekes

2015

Orvosi Hetilap

View full text Add to dashboard Cite

A sarcoma synoviale a lágyrész-sarcomák 5-10%-ában, az összes malignus daganatok 0,05-0,1%-ában fordul elő. Főként a végtagokon keletkezik, azonban bárhol kialakulhat. A betegek 50%-ában 3-5 éven belül metasztázisok jelennek meg (tüdő, nyirokcsomó, csont), sőt akár 20 év elteltével is számítani lehet a sarcoma synoviale kiújulására. Az 5 éves teljes túlélés lokalizált betegség esetén 76%, metasztatikus esetben 10%. Az életkor, daganatméret, szö-vettani altípus és a radioterápia megtörténte befolyásolja a prognózist. Az adjuváns kemoterápia szerepe nem bizonyított. Számos klinikai vizsgálat van folyamatban a lokálisan előrehaladott, relaptálódott/refrakter és metasztatikus sarcoma synoviale kezelésére. A sarcoma synoviale biológiai viselkedésének jobb megértésével a célzott kezelés és a konvencionális terápia kombinációja válhat a jövő útjává. Orv. Hetil., 2015, 156(22), 875-880.Kulcsszavak: sarcoma synoviale, kemoterápia, radioterápia, célzott kezelés Therapeutic options for synovial sarcomaSynovial sarcomas account for approximately 5 to 10% of soft tissue sarcomas and 0.05 to 0.1% of all malignant neoplasms. They predominantly affect the extremities but can occur in any part of the body. More than 50% of the patients are expected to develop metastatic disease within 3-5 years. In some patients disease recurrence may develop after 20 years. The 5-year overall survival rate is 10% for patients with metastatic disease and 76% for patients with localized one. Age, tumour size, histological subtype, and adjuvant radiotherapy infl uence prognosis. The role of adjuvant chemotherapy has not been proven yet. There are several ongoing clinical trials to determine the effi cacy of active agents used for therapy of locally advanced, relapsed/refractory or metastatic disease. Better understanding of the biological behaviour of synovial sarcomas would provide the future way for the targeted therapy in combination with conventional treatments. Rövidítések CCND1 = ciklin D1; CR = komplett remisszió; DRFS = távoli kiújulásmentes túlélés; EFS = eseménymentes (gyógyszertoxi-citás, -intolerancia, egyéb) túlélés; EpSSG = European Pediatric Soft Tissue Sarcoma Group; HDAC = hiszton-deacetiláz; IGF-1R = inzulinszerű növekedési faktor receptor-1; KT = kemoterápia; LRFS = lokális kiújulásmentes túlélés; MD = metasztatikus betegség; MFS = áttétmentes túlélés; OS = teljes túlélés; PD = progresszív betegség; PFS = progressziómentes túlélés; PR = parciális remisszió; RT = radioterápia; SD = stabil betegség; SEER = Surveillance, Epidemiology, and End Results; SS = sarcoma synoviale A sarcoma synoviale (SS) a ritka malignitások közé tartozik. A malignus daganatok 0,05-0,1%-át és a lágyrész-sarcomák 5-10%-át alkotja [1,2]. Az SS leggyakrabban a serdülőkorúak és fi atal felnőttek 15-40 éves korosztá-lyát érinti, azonban előfordulhat 10 éven aluli gyermekekben, sőt újszülöttekben is [3]. Prognosztikai faktorokTöbb munkacsoport vizsgálta az SS-ben szenvedő pá-ciensek túlélését befolyásoló prognosztikai faktorokat, amelyek közül az 5 cm vagy ann...

show abstract

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Cited by 98 publications

References 19 publications

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

A sarcoma synoviale kezelési lehetőségei

Contact Info

Product

Resources

About